Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLC

EP: 1.Dr. Giaccone on Treatment Options in NSCLC

EP: 2.Dr. Rizvi on Biomarkers of Response to Immunotherapy in NSCLC

EP: 3.Dr. West on the Use of Nivolumab/Ipilimumab in Metastatic NSCLC

EP: 4.Dr. Gandara on the Benefit of Nivolumab/Ipilimumab Plus Chemo in Metastatic NSCLC

EP: 5.Dr. Rizvi on the Implications of the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC

Now Viewing

EP: 6.Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLC

EP: 7.Dr. Raez on the Impact of PD-L1 Status on Immunotherapy Outcomes in NSCLC

EP: 8.Dr. Garon on Immunotherapy Treatment Considerations in NSCLC

EP: 9.The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer

Antoinette Wozniak, MD, FACP, FASCO, a visiting professor of medicine and associate director of clinical research at the University of Pittsburgh Medical Center (UPMC), as well as the director of the Lung Cancer Disease Unit and co-director of the UPMC Lung Cancer Center of Excellence, discusses optimizing the use of immunotherapy in patients with non–small cell lung cancer (NSCLC).

Many ongoing research efforts are examining which patients are most likely to benefit from immunotherapy, according to Wozniak. This is important, as many patients with NSCLC who are treated with this modality may not achieve clinical benefit, Wozniak says.

Another area of focus is identifying why some patients do not respond to treatment, or stop responding entirely, as well as whether utilizing 2 immunotherapy agents that target 2 different pathways will be useful in overcoming mechanisms of resistance or acquired resistance. The field hopes to answer these questions in the coming years, Wozniak concludes.